Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

Imaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than the standard of around three months—identified metabolic changes that corresponded with treatment response and progression-free survival (PFS). These study results were published in Clinical Cancer Research on Jan. 24.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart